AS
SUPN icon

Altshuler Shaham’s Supernus Pharmaceuticals SUPN Stock Holding History

Altshuler Shaham’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-801
Closed -$29K – 394
2023
Q1 		$29K Sell
801
-903
-53% -$34.7K ﹤0.01% 289
2022
Q4 		$60.8K Sell
1,704
-55
-3% -$1.91K ﹤0.01% 184
2022
Q3 		$59K Buy
+1,759
New +$57.2K ﹤0.01% 194
2022
Q2 		– Sell
-1,273
Closed -$41K – 553
2022
Q1 		$41K Buy
+1,273
New +$39K ﹤0.01% 403

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Altshuler Shaham's SUPN Position: Q2 2023 in Review

Altshuler Shaham sold out of Supernus Pharmaceuticals (SUPN) in Q2 2023, closing a stake of 801 shares — an estimated $29K sold.

Altshuler Shaham first reported a position in SUPN in Q1 2022 and held it in 4 quarters. The position peaked at $60.8K in Q4 2022. 249 funds tracked by Wall St. Rank hold SUPN as of Q2 2023.

  • Altshuler Shaham reported no remaining Supernus Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Altshuler Shaham sold 801 Supernus Pharmaceuticals shares in Q2 2023, an estimated $29K.
  • Altshuler Shaham first reported a position in Supernus Pharmaceuticals in Q1 2022 and held it in 4 quarters.
  • Altshuler Shaham's Supernus Pharmaceuticals position peaked at $60.8K in Q4 2022.
  • 249 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2023.

Based on Altshuler Shaham's 13F filing for Q2 2023, filed 24 Jul 2023.